骨転移(Bone Metastasis)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bone Metastasis Overview 9
Therapeutics Development 10
Pipeline Products for Bone Metastasis – Overview 10
Pipeline Products for Bone Metastasis – Comparative Analysis 11
Bone Metastasis – Therapeutics under Development by Companies 12
Bone Metastasis – Therapeutics under Investigation by Universities/Institutes 14
Bone Metastasis – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Bone Metastasis – Products under Development by Companies 18
Bone Metastasis – Products under Investigation by Universities/Institutes 20
Bone Metastasis – Companies Involved in Therapeutics Development 21
Ablynx NV 21
Alethia Biotherapeutics Inc. 22
Amgen Inc. 23
Amura Holdings Ltd. 24
Bayer AG 25
ChemoCentryx, Inc. 26
Debiopharm International S.A. 27
Deciphera Pharmaceuticals, LLC 28
Digna Biotech, S.L. 29
Medivir AB 30
Merrion Pharmaceuticals Plc 31
Osteologix Holdings Plc. 32
R-Pharm 33
Sigma-Tau S.p.A. 34
Bone Metastasis – Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
AB-25E9 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ADM-01 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
alendronate sodium + HPMA + paclitaxel – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
alendronate sodium + paclitaxel + PEG – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ALX-0141 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AM-3701 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AMG-161 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CCX-721 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
DCC-2909 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DCC-3014 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Debio-0719 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
denosumab – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
disitertide – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drugs to Inhibit EGFR for Bone Metastasis – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MIV-710 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MIV-711 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NBS-101 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
P-17 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
radium Ra 223 dichloride – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
RPH-203 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SST-0001 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
TPH-9 – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Vicrostatin – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
zoledronic acid – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Bone Metastasis – Recent Pipeline Updates 79
Bone Metastasis – Dormant Projects 95
Bone Metastasis – Discontinued Products 97
Bone Metastasis – Product Development Milestones 98
Featured News & Press Releases 98
May 23, 2014: Daiichi Sankyo Receives Approval in Japan for Additional Indication Related to RANMARK for Treatment of Giant Cell Tumor of Bone 98
Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders 98
Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics 99
Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo 100
Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 101
May 30, 2013: Algeta Announces First Sale Of Xofigo In US 102
Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 103
Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride 104
Oct 23, 2012: Amgen’s Xgeva Obtains Approval From NICE For Eligibility To NHS Funding 104
Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107